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Abstract
Background:  Hereditary Hemochromatosis (HH) is a genetic disease associated with iron
overload, in which individuals homozygous for the mutant C282Y HFE associated allele are at risk
for the development of a range of disorders particularly liver disease. Conformational diseases are
a class of disorders associated with the expression of misfolded protein. HFE C282Y is a mutant
protein that does not fold correctly and consequently is retained in the Endoplasmic Reticulum
(ER). In this context, we sought to identify ER stress signals associated with mutant C282Y HFE
protein expression, which may have a role in the molecular pathogenesis of HH.
Results: Vector constructs of Wild type HFE and Mutant C282Y HFE were made and transfected
into HEK293 cell lines. We have shown that expression of C282Y HFE protein triggers both an
unfolded protein response (UPR), as revealed by the increased GRP78, ATF6 and CHOP
expression, and an ER overload response (EOR), as indicated by NF-κB activation. Furthermore,
C282Y HFE protein induced apoptotic responses associated with activation of ER stress. Inhibition
studies demonstrated that tauroursodeoxycholic acid, an endogenous bile acid, downregulates
these events. Finally, we found that the co-existence of both C282Y HFE and Z alpha 1-antitrypsin
protein (the protein associated with the liver disease of Z alpha 1-antitrypsin deficiency) expression
on ER stress responses acted as potential disease modifiers with respect to each other.
Conclusion: Our novel observations suggest that both the ER overload response (EOR) and the
unfolded protein response (UPR) are activated by mutant C282Y HFE protein.
Background
Hereditary Hemochromatosis (HH) is a disorder of iron
metabolism, associated with accumulation of iron in the
body. HH is an autosomal recessive disorder resulting
from mutations in the HFE  (hemochromatosis) gene,
with clinical consequences which can range from cirrhosis
of the liver, diabetes, heart failure, arthritis to liver cancer
[1,2]. The protein encoded by this gene is similar to MHC
class I-type proteins and associates with β2-microglobulin
(β2M). β2M has been shown to play an important role in
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regulating iron absorption. The majority of HH patients
carry an HFE mutation, in which cysteine at position 282
is changed to tyrosine (C282Y) [3,4]. This mutation pre-
vents the formation of a disulfide bond in the α3 domain,
impairing the normal association of HFE with β2M. This
lack of association dramatically reduces the cell surface
expression of HFE, whereby the majority of the C282Y
mutant protein remains as high molecular weight aggre-
gates, fails to undergo late Golgi processing and subse-
quently is retained in the endoplasmic reticulum (ER)
[3,5-7]. This retention of the mutant protein in the ER
may provide a basis for the pathogenesis of this condition.
In line with this, we propose that HH associated with
C282Y HFE, may be viewed in the context of conforma-
tional diseases.
Conformational diseases arise from changes that lead to
aggregation and retention of protein with consequent late
or episodic onset of symptoms [8]. Cells respond to this
perturbation in the ER by inducing the expression of novel
genes whose products may restore ER function [9] but
may also act as proinflammatory stimulants. Regulation
of these ER stress genes occurs via two signal transduction
pathways: the ER overload response (EOR) and the
unfolded protein response (UPR). The EOR activates IKK
(inhibitor of κB kinase), which causes degradation of the
inhibitor of κB (I-κB). This allows for the activation of NF-
κB, a transcription factor that induces the expression of
genes encoding several proteins involved in death, sur-
vival and inflammatory responses [10]. The UPR pathway
involves up-regulation of glucose responsive genes such as
grp78 (Ig H chain binding protein (BiP)) in order to facil-
itate protein trafficking in the ER and the transcription fac-
tor CHOP/GADD153 (CCAAT/enhancer-binding protein
(C/EBP)) [11-13], which sensitizes cells to ER stress. In
this regard, ATF-6 is a member of the ATF/CREB basic-leu-
cine zipper (bZIP) and a proximal transducer of both
GRP78/BiP and CHOP/GADD153 [14,15]. These protec-
tive responses are designed to relieve ER stress, however
when they are ineffective, the cell undergoes apoptosis
[16]. Bcl-2 is an antiapoptotic protein located in the mem-
branes of the ER [17]. Studies have shown that ER stress
downregulates Bcl-2, culminating in cytochrome c release
and activation of caspase-3 [18,19]. Tauroursodeoxy-
cholic acid (TUDCA), an endogenous bile acid synthe-
sized in the liver's conjugation pathway of urodeoxycholic
acid (UDCA), has been demonstrated to inhibit these ER
stress-induced pathways [20-22]. It is also reported to
have a role in preventing toxicity by reducing inflamma-
tory signals [23]
The mechanisms involved in the intracellular processing
of mutant proteins are complex and not fully understood
[16,24]. Z α-1antitrypsin (A1AT) deficiency is a disorder
involving a polymerogenic mutant of the secretory glyco-
protein A1AT. The protein product of the mutant Z A1AT
gene is synthesized in hepatocytes but accumulates intra-
cellularly rather than being secreted from the cell. The
downstream effects of the expression of the mutant Z pro-
tein include ER stress resulting in mitochondrial injury
and caspase activation [25-27]. Chronic liver disease
develops in a subgroup of Z A1AT deficient individuals
associated with the mutant Z A1AT protein [28-30]. Cur-
rently, liver transplantation is the only treatment available
for severe liver disease associated with Z A1AT deficient
individuals [25,28]. The variable clinical presentations
among affected individuals, suggests an important contri-
bution of genetic and environmental disease modifiers.
While early studies have reported an association between
HH and the Z A1AT mutation which may modify the
onset and severity of the liver disorder [31,32], to date this
possible association from clinical population studies
remains unclear [33]. Indeed, molecular studies have
shown that activation of the Z A1AT UPR pathway only
occurs in the presence of a secondary stimulus. This lack
of activation of the UPR pathway has been suggested as an
explanation for the onset of the liver disorder Z A1AT defi-
ciency [34].
While C282Y HFE HH is considered a monogenic disease
its phenotypic expression varies considerably [4]. We pro-
pose that differences in the quality control systems within
the ER could explain some of this phenotypic variation. In
this study, we test this hypothesis and demonstrate that
ER stress is associated with mutant C282Y HFE expres-
sion. We determine the potential usefulness of TUDCA on
C282Y HFE induced ER stress [20-22]. Furthermore, the
co-existence of both C282Y HFE and Z A1AT protein
expression on ER stress responses were investigated (in
particular C282Y HFE ability to activate the ZA1AT UPR
pathway) as potential disease modifiers with respect to
each other.
Results
C282Y HFE model system
To confirm C282Y HFE accumulated within the ER, we
performed confocal microscopy on 24-h post transfected
cells using GFP tagged HFE protein along with antibodies
against the ER resident protein calnexin. The C282Y HFE
co-localized with calnexin (Figure. 1A), as illustrated by
merged images of the overlapping C282Y HFE/calnexin
which appears yellow, whereas the WT HFE did not co-
localize remaining green. Degradation of C282Y HFE was
found compared to WT HFE protein by GFP intensity.
This was confirmed with lysates from C282Y HFE-His tag-
transfected cells which showed degradation of the C282Y
HFE protein compared to WT HFE protein (p = 0.0012) at
24 hours (Figure. 1B).
C282Y activation of the EOR pathway
To examine the effects of C282Y HFE on the EOR path-
way, activation of NF-κB by C282Y HFE was measured byBMC Cell Biology 2007, 8:30 http://www.biomedcentral.com/1471-2121/8/30
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NF-κB luciferase reporter gene assay (Fig. 2A). NF-κB pro-
moter activation was measured in Empty vector (EV), WT
HFE-transfected, C282Y HFE-transfected and control cells
stimulated with 2.5 µM thapsigargin, 24 h post-transfec-
tion using an NF-κB-linked luciferase reporter gene. Time
course studies demonstrated that treatment for 24 h
induced optimal NF-κB promoter activity (data not
shown). C282Y HFE induced significantly higher levels of
luciferase expression compared to control or WT HFE-
transfected cells (p = 0.0009) suggesting that overexpres-
sion of C282Y HFE leads to activation of NF-κB. We fur-
ther confirmed NF-κB activation by analyzing IκB-α
degradation in the same cells, by western immunoblot-
ting. IκB-α, 24 h post-transfection, was degraded in
C282Y HFE-transfected cells compared with control or
WT HFE-transfected cells (Fig. 2B). Blots were stripped
and reprobed using a monoclonal antibody to β-Actin to
confirm equal loading (Fig. 2C).
To further elucidate these signaling events, IL-8 promoter
activity was measured using an IL-8 promoter luciferase
reporter gene in EV-transfected, WT HFE-transfected,
C282Y HFE-transfected and control cells stimulated with
2.5 µM thapsigargin. As NF-κB activation regulates the
transcription of the proinflammatory target gene IL-8,
activation of IL-8 further confirmed induction of NF-κB.
C282Y HFE induced significantly higher levels of luci-
ferase activity compared with those in WT HFE-transfected
cells (p = 0.0031) suggesting that overexpression of C282Y
HFE leads to activation of IL-8 (Fig. 2D).
C282Y HFE activates the UPR pathway and is a secondary 
stimulus activating Z A1AT UPR
We examined the effects of C282Y HFE expression on
UPR activation by investigating its effect on the grp78 pro-
moter and GRP78/BiP protein production. C282Y HFE
resulted in increased expression of a grp78-promoter-
linked luciferase reporter gene compared to WT HFE-
transfected cells (** p = 0.0011) (Fig. 3A). We confirmed
this by measuring GRP78/BiP protein production by west-
ern immunoblotting. We found that GRP78/BiP protein
production is increased in C282Y HFE-transfected cells
compared with EV or WT HFE-transfected cells (n = 3)
(Fig. 3B). Thapsigargin, a known ER agonist used as a pos-
itive control, increased grp78 promoter-linked luciferase
reporter gene and protein expression in cells. Blots were
stripped and probed for β-Actin in all these experiments.
We next examined the effect of TUDCA as an inhibitor of
C282Y HFE UPR activation. We investigated its effect on
the grp78 promoter and GRP78/BiP protein expression.
TUDCA significantly decreased levels of luciferase expres-
sion in C282Y HFE-transfected cells treated with 300 µM
TUDCA compared with those without treatment (##, p =
0.006) (Fig. 3A). Time course studies demonstrated that a
dose of 300 µM TUDCA showed decreased grp78  pro-
moter activity (data not shown). We further confirmed
TUDCA's potential effect by analyzing GRP78/BiP protein
production in the same cells by western immunoblotting.
24 h post-transfection, cells treated with 200 µM and 300
µM TUDCA had significantly decreased levels of GRP78/
BiP protein production compared to those without
TUDCA treatment (n = 3) (Fig. 3C).
Intracellular localization of WT HFE and C282Y HFE in  HEK293 transfected cells Figure 1
Intracellular localization of WT HFE and C282Y HFE 
in HEK293 transfected cells. (A) confocal microscopy of 
cells cultured for 24 h after transfection with EV-GFP, WT-
HFE GFP and C282Y-HFE GFP stained with an antibody for 
the ER-resident protein calnexin and probed with Texas Red 
labeled secondary antibody. In the merged images, the yellow 
color corresponds to areas in which the green and red stain-
ings overlap. The nucleus appears blue due to DNA staining 
with 4',6-diamidino-2-phenylindole. Scale bar, 10 µm. (B) HFE 
expression in transfected HEK293 cell lysates. HEK 293 cells 
(6 × 106) were transfected with pcDNA3.1 (empty vector, 
EV), WT HFE, or C282Y HFE (M) expression plasmids. 
C282Y HFE-His tag protein production in lysates was meas-
ured by ELISA. C282Y HFE-His tag-transfected cells showed 
markedly accelerated degradation of the C282Y HFE protein 
compared to N HFE protein (**, p = 0.0012) at 24 hours 
compared to WT HFE expression. Assays were performed in 
triplicate.
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Activation of the UPR by C282Y HFE Figure 3
Activation of the UPR by C282Y HFE. (A) HEK 293 
cells were transfected with pcDNA3.1 (empty vector, EV), 
WT HFE, or C282Y HFE (M) expression plasmids and a 
grp78-promoter luciferase reporter gene vector (grp78-luc) 
with or without pZeoSv2+ (data not shown), pMA1AT, or 
pZA1AT. As positive control or treatment, five hours post 
transfection cells were incubated with 2.5 µM thapsigargin or 
300 µM TUDCA acid for 24 h. Cells were incubated for 24 h 
in serum-complete medium. Luciferase production in cell 
lysates was measured by luminometry. Levels are expressed 
as light units (LU) per microgram of total protein. C282Y 
HFE activated grp78-luc expression (**, p = 0.0011) com-
pared to WT HFE. Treatment with TUDCA significantly 
decreased grp78-LUC expression (##, p = 0.0006) compared 
to WT HFE. Z A1AT transfection significantly increased 
grp78-LUC expression (*, p = 0.016) compared to N HFE. 
Assays were performed in triplicate and are representative 
of at least three separate experiments. (B) GRP78/BIP pro-
tein production was analyzed by western blot in cytosolic 
extracts (10 µg) from HEK293 cells transfected with 
pcDNA3.1 (lane 1), WT HFE (lane 2), C282Y HFE (lane 3) or 
HEK293 cells stimulated with 2.5 µM thapsigargin (lane 4; n = 
3). (C) GRP78/BIP protein production were analyzed by 
western blot in cytosolic extracts (10 µg) from HEK293 cells 
transfected with C282Y HFE untreated (lane 1) treated with 
200 µM TUDCA (lane 2) 300 µM TUDCA (lane 3). (D) 
GRP78/BIP protein production were analyzed by western 
blot in cytosolic extracts (10 µg) from HEK293 cells trans-
fected with pZA1AT with pcDNA3.1 (lane 1), WT HFE (lane 
2) or C282Y HFE (lane 3) or HEK293 cells stimulated with 
2.5 µM thapsigargin (lane 4; n = 3). Blots were stripped and 
probed for β-Actin to confirm equal loading.
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C282Y HFE activates EOR Figure 2
C282Y HFE activates EOR. (A) NF-κB-luciferase meas-
urement. HEK 293 cells (1 × 106) were transfected with 
pcDNA3.1 (empty vector, EV), WT HFE, or C282Y HFE (M) 
expression plasmids and an NF-κB-luciferase reporter gene 
vector. As positive control, five hours post transfection cells 
transfected with NF-κB-luciferase reporter gene vector were 
stimulated with 2.5 µM thapsigargin for 24 h. Cells were 
incubated for 24 h in serum-complete medium. Luciferase 
production in cell lysates was measured by luminometery. 
Levels are expressed as light units (LU) per microgram of 
total protein (***, p = 0.0009) compared to WT HFE. Assays 
were performed in triplicate and are representative of at 
least three separate experiments. (B) Degradation of IκB-α 
by C282Y HFE. HEK 293 cells were transfected with 
pcDNA3.1 (empty vector, EV), WT HFE, or C282Y HFE 
expression plasmids, and cytosolic extracts were prepared 
24 h post-transfection. Ten-microgram of protein was 
assayed for IκB-α degradation by Western blotting (n = 3). 
(D) HEK 293 cells (1 × 106) were transfected with pcDNA3.1 
(empty vector, EV), WT HFE, or C282Y HFE expression 
plasmids and an IL-8-luciferase reporter gene vector. As pos-
itive control, five hours post transfection cells transfected 
with IL-8-luciferase reporter gene vector were stimulated 
with 2.5 µM thapsigargin for 24 h. Cells were incubated for 
24 h in serum-complete medium. Luciferase production in 
cell lysates was measured by luminometry. Levels are 
expressed as light units (LU) per microgram of total protein 
of total protein (**, p = 0.0031) compared to WT HFE. 
Assays were performed in triplicate and are representative 
of at least three separate experiments.
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To measure the effect of C282Y HFE expression on Z A1AT
UPR activation, grp78 promoter and GRP78/BiP protein
production was measured. We found that C282Y HFE
protein increases activation of grp78 expression in the Z
A1AT cell line compared to M A1AT (*, p = 0.016) (Fig.
3A). WT HFE did not induce Z A1AT grp78 promoter acti-
vation nor did Z A1AT (without C282Y HFE) (Data not
shown) (34). To confirm these findings we examined
GRP78/BiP protein production by western immunoblot-
ting. Fig. 3D shows that GRP78/BiP protein production is
increased in the Z A1AT transfected cell line compared
with EV or M (wild type) A1AT-transfected cells. Thapsi-
gargin-treated cells were used as a positive control (Fig.
3D).
C282Y HFE activates ATF-6 and CHOP components of the 
UPR pathway and is a secondary stimulus activating the Z 
A1AT UPR pathway
We examined C282Y HFE expression on other compo-
nents of the UPR pathway. ATF-6 has direct transcrip-
tional activating properties for UPR target genes,
including the transcription factor CHOP and grp78 itself.
We found that C282Y HFE transfected cells resulted in
increased expression of a ATF6  and  CHOP-promoter-
linked luciferase reporter gene compared to WT HFE cells
(Fig. 4A and 4B) (** p = 0.0039 and ** p = 0.0011).
TUDCA significantly decreased levels of ATF6 and CHOP
luciferase expression in C282Y HFE-transfected cells
treated with 300 µM TUDCA compared to untreated (Fig.
4A and 4B) (# p = 0.0175 and ## p = 0.0067 respectively).
C282Y HFE protein expression significantly increased
ATF-6 and CHOP promoter activity in the Z A1AT cell line
compared to M A1AT (*, p = 0.02 and **, p = 0.0059,
respectively) (Fig. 4A and 4B). WT HFE did not induce Z
A1AT ATF-6 and CHOP promoter activation nor did Z
A1AT without C282Y HFE protein in control experiments
(Data not shown).
C282Y HFE induces an apoptotic response
We next examined whether C282Y HFE activation of the
UPR pathway induced cell death responses. In order to
examine potential C282Y HFE induced apoptotic
responses associated with end stage ER stress, we investi-
gated its effects on key ER stress cell death mediators.
Cytochrome c release was examined by western immuno-
blotting. We found increased cytochrome c  release in
C282Y HFE transfected cells compared to WT HFE or EV
(Fig. 5A). We confirmed this response by probing for cas-
pase-3 activation. C282Y HFE transfected cells had
enhanced activation of caspase-3 compared to WT HFE or
EV (Fig. 5B). Equal loading was confirmed by stripping
the blots and probing with an antibody to β-Actin (Fig.
5C). To confirm this finding, we examined the effect of
C282Y HFE on caspase-3 activity. HEK293 cells were
transfected with EV, WT HFE or C282Y HFE expression
plasmids. Thapsigargin was used as a positive control.
Caspase-3 activity was measured using a fluorometric cas-
pase-3 substrate. C282Y but not WT HFE induced caspase-
3 activity significantly compared to EV (*, p = 0.0363)
(Fig. 5D).
Tauroursodeoxycholic acid inhibits C282Y HFE induced 
apoptotic responses
C282Y HFE resulted in decreased expression of a bcl-2-
promoter-linked luciferase reporter gene compared to WT
HFE cells (** p = 0.004). TUDCA significantly increased
Activation of the ATF-6, CHOP by C282Y HFE Figure 4
Activation of the ATF-6, CHOP by C282Y HFE. HEK 
293 cells were cotransfected with pcDNA3.1 (empty vector, 
EV), WT HFE, or C282Y HFE (M) expression plasmids and 
(A) ATF6-promoter luciferase reporter gene vector (ATF6-
luc) (B) CHOP-promoter luciferase reporter gene vector 
(CHOP-luc), with or without pZeoSv2+ (data not shown). As 
positive control or treatment, five hours post transfection 
cells were incubated with 2.5 µM thapsigargin or 300 µM 
TUDCA for 24 h. Cells were incubated for 24 h in serum-
complete medium. Luciferase production in cell lysates was 
measured by luminometry. Levels are expressed as light units 
(LU) per microgram of total protein. C282Y HFE activated 
ATF-6 and CHOP-luc expression (**, p = 0.0039 and **, p = 
0.0011 respectively) compared to WT HFE. Treatment with 
TUDCA significantly decreased ATF6-luc and CHOP-luc 
expression (#, p = 0.0175 and ##, p = 0.0067 respectively) 
compared to WT HFE. Z A1AT transfection significantly 
increased ATF6-luc and CHOP-luc expression (*, p = 0.02 
and **, p = 0.0059) compared to WT HFE. Assays were per-
formed in triplicate and are representative of at least three 
separate experiments.
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bcl-2  luciferase activity in C282Y HFE-transfected cells
treated with 300 µM TUDCA compared to untreated (Fig.
6A) (# p = 0.0238) (Fig. 6A). C282Y HFE significantly
decreased  bcl-2  promoter activity in the presence of Z
A1AT compared to M A1AT (**, p = 0.0029) (Fig. 6A). WT
HFE did not effect bcl-2 promoter activation in the pres-
ence of Z A1AT (Data not shown). To further elucidate
both the anti-apoptotic effects of TUDCA and the effect of
ZA1AT on C282Y HFE induced apoptosis, we examined
cytochrome c release and caspase-3 activation by western
immunoblotting in C282Y HFE transfected cells treated
with 300 µM TUDCA and co-transfected with Z A1AT. In
C282Y HFE cell lines treated with 300 µM TUDCA there
was decreased cytochrome c  release compared to
untreated C282Y HFE cell lines. Furthermore, we found
increased cytochrome c  release in co-tranfected C282Y
HFE and ZA1AT cells compared to C282Y HFE cell lines.
Similarly, treatment with 300 µM TUDCA decreased this
response (Fig. 6B). To further confirm this reduced apop-
totic response by TUDCA we examined caspase-3 activity.
We found that TUDCA significantly decreased caspase-3
activation in C282Y HFE cell lines treated with 300 µM
TUDCA compared to untreated C282Y HFE cell lines. In
addition, caspase-3 activation was increased in the co-
transfected C282Y HFE and ZA1AT cell line compared to
the C282Y HFE cell line. Treatment with 300 µM TUDCA
decreased this response (Fig. 6C). Equal loading was con-
firmed by stripping the blots and probing with an anti-
body to β-Actin (Fig. 6D). We confirmed these findings by
using a caspase-3 activity assay. In this assay HEK 293 cells
were transfected with expression plasmids and thapsi-
garin was used as a positive control (Fig. 6E). We found
that Z A1AT compared to M A1AT significantly increased
caspase-3 activity in the C282Y HFE cell line (*, p  =
0.0379). Finally, we found TUDCA significantly decreased
caspase-3 activity in the C282Y HFE line, compared to
untreated C282Y HFE cell line (#, p = 0.0214).
C282Y stimulates IL-8 and MCP-1 protein production
To measure the effect of C282Y HFE protein overexpres-
sion on inflammation, MCP-1 and IL-8 protein produc-
tion was measured in the transfected cell lines. Basal and
C282Y-induced IL-8 and MCP-1 protein levels in cell
supernatants from HEK 293 cells were quantified by
ELISA (Fig. 7A and 7B). HEK cells produced a mean basal
level of 40 ± 8 pg/µg of IL-8 protein and 30 ± 12 pg/µg of
MCP-1. The actual concentration for the IL-8 and MCP-1
is shown after deduction of the HEK basal cytokine levels.
In vitro transfection with EV increased basal IL-8 and
MCP-1 expression due to the in vitro nature of this model
system. However, WT HFE did not significantly increase
either IL-8 or MCP-1 levels; whereas, C282Y HFE induced
maximal IL-8 protein production from HEK 293 cells at
24 h (time-course experiments data not shown), increas-
ing IL-8 levels to 260 ± 40 pg/µg of protein (p = 0.05) and
MCP-1 levels to 380 ± 22 pg/µg of protein (*, p = 0.0328
and *, p = 0.0149 respectively compared to WT HFE trans-
fected cells). Treatment of cell lines with TUDCA for 24 h
significantly decreased IL-8 levels to 180 ± 30 pg/µg of
protein and MCP-1 levels to 234 ± 40 pg/µg of protein (#,
p = 0.0235 and #, p = 0.0355 respectively compared to WT
HFE transfected cells).
C282Y HFE induces cytochrome c release and caspase-3 acti- vation Figure 5
C282Y HFE induces cytochrome c release and cas-
pase-3 activation. HEK293 cells (1 × 106) were transfected 
with EV, WT HFE, C282Y HFE expression plasmids or 
untransfected cells treated with 2.5 µM thapsigargin, and 
cytosolic extracts were prepared 24 h posttransfection. Ten-
microgram of protein was assayed for cytochrome c release 
(A), and caspase-3 activation (B) by western blotting (n = 3). 
C282Y HFE (M) induced cytochrome c release and process-
ing of procaspase-3 compared to EV, WT HFE or 2.5 µM 
thapsigargin treated cells. (C) To confirm equal loading blots 
were stripped and probed for β-Actin. (D) Measurement of 
caspase-3 activity in the lysates of HEK293 cells (1 × 106) 
transfected with control (empty vector), WT HFE or C282Y 
HFE expression vectors, and positive control of 2.5 µM thap-
sigargin was used. C282Y HFE significantly increased caspase-
3 activity (*, p = 0.0363) (n = 3).
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C282Y HFE stimulates IL-8 and MCP-1 protein production Figure 7
C282Y HFE stimulates IL-8 and MCP-1 protein pro-
duction. C282Y HFE increases IL-8 and MCP-1 production. 
IL-8 (A) and MCP-1 (B) protein production was measured by 
ELISA form 24-h cell supernatants from HEK293 cells trans-
fected with EV, N HFE, or C282Y HFE cDNAs with or with-
out treatment of 300 µM TUDCA. Values are expressed as 
picograms per microgram of total protein. C282Y HFE 
increased IL-8 and MCP-1 protein expression (*, p = 0.0328 
and *, p = 0.0149 respectively) compared to WT HFE. Treat-
ment with TUDCA significantly decreased IL-8 and MCP-1 
protein expression (#, p = 0.0235 and #, p = 0.0355 respec-
tively) compared to WT HFE. Assays were performed in 
triplicate and are representative of at least three separate 
experiments.
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Taurosodeoxycholic acid inhibits C282Y HFE induced apop- totic responses Figure 6
Taurosodeoxycholic acid inhibits C282Y HFE 
induced apoptotic responses. (A) HEK 293 cells (1 × 106) 
were transfected with pcDNA3.1 (empty vector, EV), WT 
HFE, or C282Y HFE (M) expression plasmids and an bcl-2-
luciferase reporter gene vector. As positive control, five 
hours post transfection cells were stimulated with 2.5 µM 
thapsigargin for 24 h. Cells were incubated for 24 h in serum-
complete medium. Luciferase production in cell lysates was 
measured by luminometry. Levels are expressed as light units 
(LU) per microgram of total protein. C282Y HFE decreased 
bcl-2-luc expression (**, p = 0.004) compared to WT HFE. 
Treatment with TUDCA significantly increased bcl-2-luc 
expression (#, p = 0.0238) compared to WT HFE. Z A1AT 
transfection significantly decreased bcl-2-luc expression **, p 
= 0.0029 compared to WT HFE transfected with M A1AT. 
Assays were performed in triplicate and are representative 
of at least three separate experiments. (B) HEK293 cells (1 × 
106) were transfected with C282Y HFE (M) with or without 
Z A1AT expression plasmids. Transfected cells were 
untreated or treated with 300 µM TUDCA, and cytosolic 
extracts were prepared 24 h posttransfection. (B) Ten-
microgram of protein was assayed for cytochrome c release, 
and (C) caspase-3 activation by western blotting (n = 3). Incu-
bation with TUDCA markedly inhibited cytochrome c 
release and processing of procaspse-3. (D) Blots were 
stripped and probed with β-Actin to confirm equal loading. 
(E) Measurement of caspase-3 activity in the lysates of 
HEK293 cells (1 × 106) transfected with C282Y HFE (M) and 
either Z A1AT HFE or M A1AT expression plasmids. Trans-
fected cells were untreated or treated with 300 µM TUDCA. 
Positive control of 2.5 µM thapsigargin used. Z A1AT 
increased C282Y HFE (M) caspase-3 activity compared to M 
A1AT (*, p = 0.0379) and treatment with 300 µM TUDCA 
significantly decreased C282Y HFE (M) induced caspase-3 
activity compared to untreated (#, p = 0.0214).
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Discussion
In this study, a HEK293 cell line model system transiently
expressing WT HFE or its C282Y mutant counterpart was
used to determine the ER stress mechanisms associated
with C282Y HFE production and retention. We demon-
strated that the C282Y mutant protein co-localized with
the ER resident protein calnexin and undergoes marked
degradation compared to WT HFE, providing a suitable
model of study for the C282Y HFE protein. C282Y HFE
mutant protein accumulates in the ER and middle Golgi
compartment, and consequently undergoes degradation
[5,6,38-40]. Mutant proteins with such impaired egress
have been shown to cause ER stress in a variety of disor-
ders, which in turn may give rise to a variety of stress path-
ways such as EOR, UPR activation and cellular death [41-
43].
Upregulation of the EOR pathway leads to activation of
the transcription factor NF-κB [10]. In this study we found
that C282Y HFE protein induced NF-κB, which conse-
quently resulted in a marked increase in protein produc-
tion of both interleukin-8 (IL-8) and monocyte
chemotatic protein-1 (MCP-1), along with increased tran-
scriptional activation of IL-8 in C282Y HFE-expressing cell
line. IL-8 has been shown to be an important mediator in
various diseases [44,45]. MCP-1 is secreted by a variety of
cells as a response to several inflammatory stimuli and
activates and attracts monocytes/macrophages [46]. Fur-
thermore, MCP-1 concentrations are deregulated in
patients with alcoholic hepatitis or cirrhosis [46,47] and
in patients with hepatitis C [48]. These findings suggest
that the pathology of HH in C282Y/C282Y HFE patients
may involve an aberrant inflammatory action [49,50].
Indeed, in this regards Lee et al found that HFE expression
was increased during ER stress, induced by serum depriva-
tion, menadione and β-amyloid. This increase in HFE
expression was independent of transferrin receptor and
ferritin. Furthermore, the labile iron pool was consistently
decreased when HFE expression was increased, suggesting
that the observed induction of HFE has a protective func-
tion by limiting cellular iron exposure during stress
[51,52].
UPR pathway involves up-regulation of the secretory
pathway's capacity to process proteins and entails the
transcriptional up-regulation of a co-ordinately expressed
set of genes encoding ER chaperones, enzymes, and struc-
tural components of the ER. The UPR pathway culminates
in the expression of glucose-responsive genes (grp) such
as, grp78. Expression of the ER charpone grp78/BiP is a
classical marker for UPR activation in mammalian cells.
The grp78  promoter contains a consensus binding site
called the ER stress response element; recognised by ATF6,
a transcription factor specifically activated by ER stress.
Several lines of evidence support the essential role of ATF6
in the ER stress response and have revealed it to be a prox-
imal transducer of GRP78/BiP [14]. Recent studies of pro-
teomic analysis of hepatic iron overload in mice have
shown increased levels of GRP78/Bip protein [53]. This
upregulation in response to iron excess has been demon-
strated previously in human cells and it has been sug-
gested that up-regulation of GRP78/Bip may indicate
increased demand for re-folding or retention of proteins
in the ER of iron-overloaded cells [54]. The UPR is also
known to up-regulate CHOP, which is generally linked to
ER stress. CHOP protein belongs to the CCAAT/enhancer-
binding protein (C/EBP) family of transcription factors
and is thought to play a critical role in cell survival or cell
death during ER stress [55]. Prolonged activation of the
UPR responses is known to result in cell death. Studies by
Hacki et al, suggested that perturbing ER functions
induces a specific crosstalk between the ER and mitochon-
dria [56]. It is also worth noting that constitutive activa-
tion of NF-κB promotes survival of a range of cells,
including B cells, hepatic cells and cancer cells. However,
whereas NF-κB is most commonly involved in suppress-
ing apoptosis by transactivating the expression of anti
apoptotic genes, it is associated with promoting pro-
grammed cell death in response to ER stress via the EOR
pathway by calcium release from the ER, resulting in mito-
chondrial dysfunction and apoptosis [57-59]. In neuronal
degenerating disease, ER stress results in activation of NF-
κB, up-regulation of GRP78 protein levels, and ensuing
apoptotic cell death due to the expression of mutant pro-
tein [60]. The data in this study reveals a potential role for
NF-κB in C282Y HFE mediated cellular death.
TUDCA is a non-toxic compound which is known to be
effective in preventing cytotoxic processes. It has been
demonstrated to inhibit activation of GRP78 and caspase-
3, along with cytochrome c release. TUDCA stabilizes the
lipid and protein structure of mitochondrial outer mem-
branes, thus inhibiting Bax binding to the outer mem-
brane [20]. Indeed, mitochondrial-derived reactive
oxygen species may be involved [61,62] as suggested by
recent studies which report that TUDCA prevents the gen-
eration of ROS [20]. The potential of TUDCA to prevent
apoptosis and caspase activation may prove beneficial in
protecting cells predisposed to disruptions in the ER.
Cytochrome c release and caspase-3 activation along with
decreased bcl-2 promoter activity suggest the damaging
action of mutant C282Y protein in cellular stress and
therefore TUDCA may protect cells during C282Y HFE
protein induced stress.
A variable clinical presentation among C282Y
homozygous individuals suggests an important contribu-
tion of disease modifiers acting on the same signalling
pathways. Indeed, while the C282Y mutation results in anBMC Cell Biology 2007, 8:30 http://www.biomedcentral.com/1471-2121/8/30
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altered disease phenotype, mice studies have shown that
the C282Y mutation does not completely disrupt the
function of HFE, emphasising the importance of addi-
tional insults. Furthermore, activation of the UPR path-
way can have a protective role [9]. Therefore, it may be
suggested that activation of this pathway by C282Y HFE
protein expression as shown in this report might explain
the milder phenotype of C282Y HFE mice compared to a
similar but more severe phenotype of the HFE knockout
mice [63]. Z A1AT deficiency represents a possible genetic
insult which is known to act on the EOR and UPR path-
ways and serves as an excellent model for conformational
disease [64,65]. Recent work has revealed the lack of UPR
activation by mutant Z A1AT, suggesting it is unlikely that
mutant Z A1AT is "sensed" by the machinery of the UPR.
Indeed, the signal appears not to be transmitted as a result
of a block in the afferent or efferent components of the
response, demonstrated by a lack of increased GRP78
activity. However, these studies have shown that Z A1AT
UPR activation is found as a result of a secondary stimu-
lus, revealing its activation in the presence of known
chemical stress inducers [34]. We wanted to examine the
co-existence of both C282Y HFE and Z A1AT in our in vitro
cell model system, whereby the C282Y HFE could act as a
genetic insult in the context of secondary stimuli acting on
the Z A1AT UPR pathway. Our findings indicate the
potential for C282Y HFE to activate the Z A1AT UPR path-
way (Fig. 3A and 3D), thus implicating C282Y HFE as a
factor which may 'trigger' and/or explain part of the clini-
cal expression of Z A1AT deficiency and vice versa. Recent
reports, have suggested that the heterozygous carrier state
for the mutant Z gene, found in 1.5 % to 3% of the popu-
lation, is not itself a common cause of liver injury but may
be a modifier gene for other liver diseases [27]. Indeed, a
large patient population study recently indicated that the
Z A1AT heterozygous state may have a role in worsening
liver disease [66].
Conclusion
This study examines the effect of C282Y HFE protein
expression upon specific ER stress pathways. It is possible
that differences in the quality control systems within the
ER, could explain some of the phenotypic variation
observed in HH. To test this hypothesis there is a need to
understand how C282Y HFE protein expression interacts
with the ER quality control components. While the results
from our study are interesting and novel, potential limita-
tions in regards applicability of our findings to the human
condition must be considered. Our observations might be
influenced by the magnitude of expression of the mutant
protein, the cell line chosen for the studies and the relative
magnitude of β2M expression. Nonetheless, these findings
of intracellular stress mechanisms associated with C282Y
HFE raises the prospect of a better understanding of the
pathogenesis of HH and as a model system may serve as a
platform to test the effects of the UPR on proteins
involved in iron metabolism.
Methods
C282Y HFE model system
Human Embryonic Kidney (HEK) 293 cells (American
Type Culture Collection, Manassas, VA) were cultured in
Eagle's Minimum Essential Medium supplemented with 2
MM L-glutamine, 1% non-essential amino acids, 1%
sodium pyruvate and 10% foetal calf serum (Invitrogen,
Scotland). HEK 293 cells were transiently transfected with
eukaryotic expression vectors containing a normal HFE or
mutant C282Y cDNA. The cDNA sequence obtained from
GenBank (U60319) was assembled using synthetic oligo-
nucleotides (Geneart, Regensburg, Germany).
The fragment was cloned into pcDNA3.1 (Invitrogen)
using BamHI and NotI restriction sites with or without the
cDNA for green fluorescent protein or His tag to generate
plasmids expressing fluorescent-tagged (GFP) or His tag
versions of wild-type (WT) HFE and C282Y HFE (M). The
plasmid DNA was purified (Pure Yield™ Plasmid
Midiprep, Promega) from transformed Escherichia coli.
The C282Y mutation was inserted utilizing QuickChange
site-directed mutagenesis kit (Stratagene) with mutagenic
primers encoding the appropriate G to A base change. The
final constructs were verified by sequencing. The M A1AT
and Z A1AT vectors were made whereby the M A1AT
cDNA was cloned on a 1256-bp EcoRI/XhoI fragment into
pZeoSV2+  (Invitrogen, Carlsbad, CA) to generate
pMA1AT. Z A1AT was constructed by site-directed muta-
genesis using the QuikChange site-directed mutagenesis
kit (Stratagene) and mutagenic primers encoding the
Glu342 → Lys mutation (bold) and a ClaI restriction site
(underlined) for screening (forward primer, 5'-GCT GTG
CTG ACC ATC GATAAG AAA GGG ACT GAA GCT GCT G-
3'). Putative mutants were isolated, and their sequences
were verified.
Transfection
HEK293 cells were seeded at 1 × 106 on six-well plates or
6 × 106 in flasks 24 h before transfection. Transfections
were performed with GeneJuice transfection reagent
(Novagen) in a 1:1 ratio according to the manufacturer's
instructions for 1 h with 1 µg pcDNA3.1 (empty vector),
pWT HFE, or pC282YHFE with or without 1 µg pZeoSv2+
(empty vector), pMA1AT, or pZA1AT. After supplementa-
tion with complete medium, cells were incubated for 24
hours. Uniform transfection efficiencies were verified by
measuring β-galactosidase activity using the substrate o-
nitrophenyl-β-D-galactopyranoside from a cotransfected
β-galactosidase expression plasmid.BMC Cell Biology 2007, 8:30 http://www.biomedcentral.com/1471-2121/8/30
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Confocal Microscopy
Cells for confocal microscopy were grown on chamber
slides (Labtek) and transfected with green fluorescent-
tagged versions of WT HFE and C282Y HFE as described
above. At 8, 16 and 24 h after transfection, cells were
washed, fixed with paraformaldehyde for 30 min at room
temperature, washed again, and blocked for 60 min with
phosphate-buffered saline (PBS) containing 10% bovine
serum albumin, 0.1% Triton X-100, and 0.1% sodium
azide, and then incubated in primary antibody goat poly-
clonal IgG calnexin (Santa Cruz Biotechnology) for 90
min. Cells were washed again, incubated with secondary
to goat IgG Texas Red (Abcam) for 60 min, washed, and
mounted in Fluorescent mounting medium (DakoCyto-
mation, CA, U.S.A) containing 2% 1,4-diazabicyclo
[2.2.2]octane (Sigma) and 3 µg/ml 4',6-diamidino-2-phe-
nylindole (Sigma). Pictures were taken using the FV1000
Olympus confocal laser microscope.
C282Y HFE protein production measurement by sandwich 
ELISA
C282Y HFE-His tag protein production in lysates was
measured by sandwich ELISA using mouse monoclonal
IgG Penta-His (Qiagen), rabbit anti-mouse IgG (Qiagen,
UK), goat anti-rabbit IgG HRP (DAKO, Carpenteria, CA),
and ABTS substrate (Zymed Laboratories, San Francisco,
CA). After absorbance reading at 405 nm on a multilabel
counter (Victor2; Wallac, Gaithersburg, MD), C282Y HFE-
His tag protein levels were calculated from both an Multi-
ple tag cell lysate (GenScript Corporation, NJ) and 6 × His
protein ladder (Qiagen, UK) standard curve. Values are
expressed as nanograms per 6 × 106 cells.
Reporter gene assays
HEK cells were seeded at 1 × 106 cells/well and were
cotransfected with 1 µg of pcDNA3.1 (empty vector),
pWTHFE, or pC282YHFE; with or without 1 µg pZeoSv2+
(empty vector), pMA1AT, or pZA1AT and either 1 µg of
grp78 promoter-linked luciferase plasmid (a gift from K.
Mori (Laboratory of Molecular Neurobiology, Graduate
School of Biostudies, Kyoto University, Kyoto, Japan))
[12], or ATF6 promoter-linked luciferase plasmid (a gift
from R. Prywes (Department of Biological Sciences,
Columbia University, New York, U.S.A)) [14] or CHOP
promoter-linked luciferase plasmid (a gift from P.
Fafournoux (Unité de Nutrition Cellulaire et Moléulaire,
INRA de Theix, Champanelle, France) [35] or bcl-2 a gift
from L. Boxer (Center for Molecular Biology in Medicine,
Department of Medicine, Stanford University School of
Medicine, Stanford, California, U.S.A) [36], or IL-8 luci-
ferase reporter gene plasmid or an (NF-κB)5-luciferase
reporter gene plasmid [34]. Transfections were incubated
for 1 h at 37°C. Cells were then supplemented with addi-
tional growth medium (4 ml/well) for 24 h at 37°C
before being left untreated or treated with 2.5 µM thapsi-
gargin or 200 µM/300 µM tauroursodeoxycholic acid for
24 h. Cells were lysed with reporter lysis buffer (Promega;
250  µl/well), protein concentrations were determined
[37], and reporter gene activity was quantified by lumi-
nometry (Victor 1420 multilabel counter; Wallac) using
the Promega luciferase assay system according to the man-
ufacturer's instructions. Reporter gene expression was
expressed as light units per microgram of total protein.
Western blot analysis
Cell cytoplasmic extracts (10 µg of protein) were sepa-
rated by electrophoresis on 10% SDS-polyacrylamide gels
and transferred to a nitrocellulose membrane (Sigma-
Aldrich) in 20 mM Tris, 150 mM glycine, 0.01% SDS, and
20% (v/v) methanol at 75 mA for 2 h using a semidry elec-
trophoretic blotting system. Nonspecific binding was
blocked with 0.2% I-Block (Tropix, Bedford, MA) and PBS
containing 0.1% Tween 20 (Sigma-Aldrich). Immunore-
active proteins were detected by incubating the membrane
with a specific Ab (GRP78 (N-20) (from Santa Cruz Bio-
technology); mouse anti-human IκBα (from Cell Signal-
ing Technologies, Beverly, MA); Mouse anti-human
cytochrome c (from BD Biosciences); Rabbit anti-human
caspase 3 (from Affiniti Research Products Ltd.); mouse
anti-actin (Actin (Ab-1) Kit) (from Oncogene Research
Products). After six 5-min washes with PBS containing
0.1% Tween 20, immunoreactive proteins were detected
using an appropriate alkaline phosphatase-conjugated
secondary Ab (Promega) and CDP-Star chemiluminescent
substrate solution (Sigma-Aldrich) according to the man-
ufacturer's instructions.
Caspase-3 activity assays
Caspase-3 activity was measured using the flourogenic
substrate Ac-DEVD-AMC (Caspase-3 Substrate II, Calbio-
chem). Cells were lysed in 250 µl of 25 mM Hepes, 5 MM
edta, 0.1% Chaps, 5 mM ATP, pH 7.5, with 2 mM DTT.
Equal amounts of protein from each sample were incu-
bated with substrate (50 µM, final concentration) in lysis
buffer for 30 min at 37°C, and fluorescence (substrate
turnover) was determined by excitation at 355 nm and
emission at 460 nm. Activity is expressed as ∆ fluorescence
units (dFU)/µg protein. Assays were performed in tripli-
cate.
IL-8 and MCP-1 protein production
The human cell line HEK293 was transfected as already
described. Cells were then left untreated or treated with
300  µM tauroursodeoxycholic acid for 24 h. IL-8 and
MCP-1 protein concentrations in cell supernatants were
determined by ELISA (R&D Systems, Minneapolis, MN).
Protein concentrations were determined by the method of
Bradford [37]. Cell viability, assessed by trypan blue
exclusion, was >95% in all studies. Results are expressed
as picograms per microgram of total protein.BMC Cell Biology 2007, 8:30 http://www.biomedcentral.com/1471-2121/8/30
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Statistical analysis
Data were analyzed with the PRISM 4.0 software package
(GraphPad, San Diego, CA). Results are expressed as the
mean ± SE, and were compared by t test or ANOVA as
appropriate. Differences were considered significant when
the p value was ≤ 0.05.
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